Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-801 12-Week Extension in NAFLD
NCT05292911Phase 1Completed
- Sponsor
- Altimmune, Inc.
- Start
- Mar 2022
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pemvidutide in non-alcoholic fatty liver disease (NAFLD) and obesity (4 arms), sponsored by Altimmune, Inc. Primary endpoint: Treatment-Emergent Adverse Events at Day 110. Started Mar 2022; status: completed.
02
Drugs
pemvidutide
03
Conditions
non-alcoholic fatty liver disease (NAFLD)obesity
Beyond the preview
Go deeper on NCT05292911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05292911.